Search Results

TB5 10 mg  | 99.82%

TargetMol

TB5 is a potent, selective and reversible inhibitor of hMAO-B.

More Information Supplier Page

×

TB5

TB5 100 mg  | 99.82%

TargetMol

TB5 is a potent, selective and reversible inhibitor of hMAO-B.

More Information Supplier Page

×

TB5

Src Inhibitor 1 5 mg  | 100.00%

TargetMol

Src Inhibitor 1 is a potent and selective dual site Src tyrosine kinase inhibitor.

More Information Supplier Page

×

Src Inhibitor 1

Src Inhibitor 1 50 mg  | 100.00%

TargetMol

Src Inhibitor 1 is a potent and selective dual site Src tyrosine kinase inhibitor.

More Information Supplier Page

×

Src Inhibitor 1

Src Inhibitor 1 25 mg  | 100.00%

TargetMol

Src Inhibitor 1 is a potent and selective dual site Src tyrosine kinase inhibitor.

More Information Supplier Page

×

Src Inhibitor 1

Src Inhibitor 1 10 mg  | 100.00%

TargetMol

Src Inhibitor 1 is a potent and selective dual site Src tyrosine kinase inhibitor.

More Information Supplier Page

×

Src Inhibitor 1

Compound 401 5 mg  | 99.76%

TargetMol

Compound 401 is a synthetic DNA-PK inhibitor (IC50 = 0.28 μM) that also targets mTOR but not PI3K.

More Information Supplier Page

×

Compound 401

TB5 25 mg  | 99.82%

TargetMol

TB5 is a potent, selective and reversible inhibitor of hMAO-B.

More Information Supplier Page

×

TB5

TB5 50 mg  | 99.82%

TargetMol

TB5 is a potent, selective and reversible inhibitor of hMAO-B.

More Information Supplier Page

×

TB5

Solcitinib 5 mg  | Purity Not Available

TargetMol

Solcitinib (GSK2586184, GLPG0778) is a JAK1 inhibitor. Solcitinib may be potentially used for the treatment of psoriasis, ulcerative colitis, and systemic lupus erythematosus.

More Information Supplier Page

×

Solcitinib